微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 82.48% | 3.27% | 0.45% | 16/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 82.11% | 19.85% | -0.04% | 19/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 82.15% | 22.52% | 1.56% | 18/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 80.89% | 22.04% | 1.28% | 18/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 79.87% | 32.56% | 16.57% | 18/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 68.51% | 33.84% | 2.19% | 36/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 67.05% | 37.33% | 1.16% | 37/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 66.28% | 47.02% | 10.01% | 40/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 60.25% | 35.97% | 17.7% | 49/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 51.19% | 16.58% | 4.85% | 74/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 48.82% | 10.67% | 8.3% | 81/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 45.08% | 3.54% | 1.74% | 92/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 44.31% | 1.27% | 0.92% | 90/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 43.91% | 22.28% | -0.47% | 92/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 44.12% | 24.02% | 1.32% | 88/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 43.54% | 28.78% | -0.49% | 91/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 43.75% | 18.16% | 21.85% | 86/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 35.91% | -0.15% | 0.95% | 117/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 35.57% | -6.17% | 5.2% | 102/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 33.81% | -7.09% | -8.69% | 114/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 37.03% | 25.88% | 2.96% | 91/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 35.96% | 9.13% | -5.14% | 112/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 37.91% | 4.01% | 4.18% | 93/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 36.39% | 10.65% | 23.71% | 103/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 29.42% | -8.03% | -10.74% | 95/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 32.96% | 3.19% | -9.58% | 112/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 36.45% | -42.4% | 10.83% | 84/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 32.89% | -52.37% | 2.83% | 96/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 31.98% | -53.38% | 0.14% | 89/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 31.94% | -55.26% | -49.53% | 109/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 63.28% | -14.21% | -8.36% | 32/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 69.05% | -5.71% | 0.65% | 23/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 68.61% | -4.31% | -3.9% | 23/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 71.39% | 0.7% | -3.22% | 23/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 73.77% | 2% | 0.72% | 15/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 73.24% | 5.64% | 2.15% | 14/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 71.7% | 2% | 1.14% | 13/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 70.89% | 2.6% | 2.25% | 17/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-06-30 | 69.33% | 2% | 0.34% | 15/157 | 46.26% | 贝达药业 | 95.58% | 行业排名> |